Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation

Starting soon · Early Phase 1

Conditions studied: ABO Blood Type Incompatible Kidney Transplantation

In brief

The goal of this clinical trial was to determine whether the Bites drugs (Blinatumomab and Teclistamab) can reduce blood group antibodies in recipients of living donor blood-incompatible kidney transplants for pretransplant conditioning. It will also understand the safety of Bites drugs in the transplant population. The main questions it aims to answer include: Can Bites effectively reduce blood group antibodies? What are the safety concerns that participants may have when using Bites? Participants will: Be given Blinatumomab and Teclistamab at the standard dose prescribed by the manufacturer before surgery, and blood group antibodies were rechecked every two weeks to two months. The adverse drug reactions and the times of rescue were recorded.

Key facts

Study ID: NCT07706205
Run by: West China Hospital
People needed: 20
Starts: 2026-09-01
Expected to finish: 2028-12-31
Last updated by the study team: 2026-07-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥18 years old and ≤65 years old, regardless of gender
End-stage renal disease (ESRD) diagnosed clinically and pathologically, estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m², or undergoing maintenance dialysis (hemodialysis or peritoneal dialysis) for ≥3 months
Plan to receive ABO-incompatible living donor kidney transplantation (ABOi-LDKT), and the matching has been approved by the organ transplantation ethics committee and technical committee of the hospital
Pre-existing anti-donor ABO blood group antibody titer (IgG+IgM) ≥1:16 (determined by standard tube method or microcolumn gel method)
able to understand study procedures, provide written informed consent, and be willing and able to comply with the study visit schedule and laboratory examination requirements

You may not qualify if…

patients allergic to the components of rituximab, teritumumab and berintuomab;
Hematologic diseases or myelosuppression (ANC < 1.0×10⁹/L, PLT < 75×10⁹/L);
multi-organ recipients, such as patients undergoing or having bone marrow transplantation or other organ transplantation at the same time;
acute active infection (including HBV, HCV, HIV, uncontrolled bacterial/fungal infection);
Severe cardiac dysfunction (NYHA class III-IV)
known or suspected hereditary complement deficiency
abnormal liver function: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or glutamyl transpeptidase (GGT) > 3 times the upper limit of normal (ULN); Or alkaline phosphatase (ALP) or total bilirubin values greater than 1.5 times the upper limit of normal (ULN).
Central nervous system diseases: epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis or central nervous system vasculitis, visual impairment, cranial neuropathy requiring intervention, etc.
complicated with other uncontrolled malignant tumors;
women who are pregnant, breastfeeding or planning to become pregnant;
patients with poor compliance before and after surgery, or unable to cooperate with treatment and research due to other mental diseases;
Patients who were not eligible for the study for other reasons according to the investigator's judgment.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.